Welcome

Pfizer, Johnson & Johnson Settle Antitrust Suit Over Remicade

July 22, 2021, 5:40 PM

Pfizer Inc. settled with Johnson & Johnson, ending a four-year battle over J&J’s alleged use of exclusionary contracts to block biosimilar competition to its immunosuppressive drug Remicade.

The settlement allows Pfizer to continue selling its own drug, Inflectra, in the U.S., Pfizer said in a statement provided to Bloomberg Law Thursday. The drugmaker didn’t reveal the terms of the deal.

The case, filed in 2017, is one of several antitrust lawsuits over biosimilars—less expensive versions of complex biologic drugs, which are made using living cells.

Pfizer alleged that J&J violated antitrust laws by threatening to withhold rebates from United ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.